The use of serotonergic drugs to treat obesity - Is there any hope?

Drug Design, Development and Therapy

Volumn , Issue 5, 2011, Pages 95-109

  Bello, Nicholas T ^a   Liang, Nu Chu ^b  

^a RUTGERS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

5 hydroxytryptamine; Dexfenfluramine; Dorsal raphe; Fenfluramine; Satiety; Serotonin 1b

Indexed keywords

ADP 356; AMPHETAMINE; DEXFENFLURAMINE; FENFLURAMINE; LORCASERIN; PHENTERMINE; PLACEBO; SEROTONIN; SEROTONIN AGONIST; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; SEROTONIN RECEPTOR AFFECTING AGENT;

BINDING AFFINITY; CARCINOGENICITY; CEREBROVASCULAR ACCIDENT; CONSTIPATION; DEPRESSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FEEDING BEHAVIOR; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HEART RATE; HUMAN; HYPERTENSION; INSOMNIA; LIVER INJURY; LONG TERM CARE; NONHUMAN; OBESITY; OFF LABEL DRUG USE; PULMONARY HYPERTENSION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VALVULAR HEART DISEASE; XEROSTOMIA; ANIMAL; CHEMISTRY; DRUG EFFECT; PHYSIOLOGY;

ANIMALS; FEEDING BEHAVIOR; HUMANS; OBESITY; SEROTONIN; SEROTONIN AGENTS;

EID: 79953023217     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S11859     Document Type: Review

References (170)

1. Marcason W. What are the latest figures for state-specific prevalence of obesity in the United States? J Am Diet Assoc. 2007;107(1): 168.
2. Neufeld LM, Hernandez-Cordero S, Fernald LC, Ramakrishnan U. Overweight and obesity doubled over a 6-year period in young women living in poverty in Mexico. Obesity (Silver Spring). 2008;16(3): 714-717.
3. Zaninotto P, Head J, Stamatakis E, Wardle H, Mindell J. Trends in obesity among adults in England from 1993 to 2004 by age and social class and projections of prevalence to 2012. J Epidemiol Community Health. 2009;63(2):140-146.
4. Han JC, Lawlor DA, Kimm SY. Childhood obesity. Lancet. 2010:15;375 (9727):1737-1748.
5. Jafar TH, Qadri Z, Islam M, Hatcher J, Bhutta ZA, Chaturvedi N. Rise in childhood obesity with persistently high rates of undernutrition among urban school-aged Indo-Asian children. Arch Dis Child. 2008;93(5):373-378.
6. Popkin BM. Recent dynamics suggest selected countries catching up to US obesity. Am J Clin Nutr. 2010;91(1):284S-288S.
7. World Health Organization; Obesity and overweight fact sheet no. 311. WHO website. 2006. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed February 4, 2011.
8. James WP. WHO recognition of the global obesity epidemic. Int J Obes (Lond). 2008;32 Suppl 7:S120-S126.
9. Ford ES, Mokdad AH, Giles WH, Galuska DA, Serdula MK. Geographic variation in the prevalence of obesity, diabetes, and obesityrelated behaviors. Obes Res. 2005;13(1):118-122.
10. Hursting SD, Berger NA. Energy balance, host-related factors, and cancer progression. J Clin Oncol. 2010;28(26):4058-4065.
11. Li F, Fisher KJ, Harmer P. Prevalence of overweight and obesity in older US adults: estimates from the 2003 Behavioral Risk Factor Surveillance System survey. J Am Geriatr Soc. 2005;53(4):737-739.
12. NHLBI Obesity Education Initiative. The Practical Guide Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH Publication No. 00-4084. 2000.
13. Mayor S. NICE requires primary care trusts to tackle prevention and management of obesity. BMJ. 2006;333(7581):1239.
14. Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17):1566-1575.
15. Andersson C, Weeke P, Fosbol EL, et al. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism. 2009;58(8):1109-1115.
16. Mertens IL, van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res. 2000;8(3): 270-278.
17. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194-1199.
18. Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic and Bariatric Surgery Medical Guidelines for Clinical Practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Surg Obes Relat Dis. 2008;4(5 Suppl):S109-S184.
19. Fontana MA, Wohlgemuth SD. The surgical treatment of metabolic disease and morbid obesity. Gastroenterol Clin North Am. 2010;39(1): 125-133.
20. Guller U, Klein LV, Hagen JA. Safety and effectiveness of bariatric surgery: Roux-en-Y gastric bypass is superior to gastric banding in the management of morbidly obese patients. Patient Saf Surg. 2009; 3(1):10.
21. Sjostrom L, Gummesson A, Sjostrom CD, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10(7):653-662.
22. Picot J, Jones J, Colquitt JL, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess. 2009;13(41):1-190, 215-357, iii-iv.
23. Jensen C, Flum DR. The costs of nonsurgical and surgical weight loss interventions: is an ounce of prevention really worth a pound of cure? Surg Obes Relat Dis. 2005;1(3):353-357.
24. Salem L, Jensen CC, Flum DR. Are bariatric surgical outcomes worth their cost? A systematic review. J Am Coll Surg. 2005;200(2): 270-278.
25. Tindle HA, Omalu B, Courcoulas A, Marcus M, Hammers J, Kuller LH. Risk of suicide after long-term follow-up from bariatric surgery. Am J Med. 2010;123(11):1036-1042.
26. Basu A. Forecasting distribution of body mass index in the United States: is there more room for growth? Med Decis Making. 2010; 30(3):E1-E11.
27. Guidance for the clinical evaluation of weight-control drugs. Crit Rev Food Sci Nutr. 2001;41(1):91-94.
28. Hadvary P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J. 1988;256(2):357-361.
29. Ko J, Small DM. Behavior of tetrahydrolipstatin in biological model membranes and emulsions. J Lipid Res. 1997;38(8):1544-1552.
30. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281(3): 235-242.
31. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994; 56(1):82-85.
32. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr. 1999;69(6):1108-1116.
33. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 2008;31(1):53-65.
34. McClendon KS, Riche DM, Uwaifo GI. Orlistat: current status in clinical therapeutics. Expert Opin Drug Saf. 2009;8(6):727-744.
35. Connery TP. Orlistat over the counter: Is it worth it? BMJ. 2008; 336(7634):7.
36. EMA. European Medicines Agency. Questions and answers on the suspension of medicines containing sibutramine. EMA/H/A-107/1256. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/ Sibutramine_107/WC500094238.pdf. Accessed February 4, 2011.
37. ® (Sibutramine) in the US. Press Release; 2010 Oct 8. http://www.abbott.com/global/url/pressRelease/en_US/Press_Release_0908.h tm. Accessed February 4, 2011.
38. McNeely W, Goa K.L. Sibutramine. A review of its contribution to the management of obesity. Drugs. 1998;56(6):1093-1124.
39. Nelson DL, Gehlert DR. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine. 2006; 29(1):49-60.
40. Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord. 1998;22 Suppl 1:S18-S28; discussion S29.
41. Buckett WR, Thomas PC, Luscombe GP. The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(5):575-584.
42. Rowley HL, Butler SA, Prow MR, et al. Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats. Synapse. 2000;38(2):167-176.
43. Wortley KE, Heal DJ, Stanford SC. Modulation of sibutramine-induced increases in extracellular noradrenaline concentration in rat frontal cortex and hypothalamus by alpha2-adrenoceptors. Br J Pharmacol. 1999;128(3):659-666.
44. Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. Exp Clin Endocrinol Diabetes. 2004;112(4):201-207.
45. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract. 2001;50(6):505-512.
46. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ. 2002;166(10):1307-1308.
47. Meridia (sibutramine hydrochloride monohydrate) capsules. [Package insert] Document 600-452107. 2010.
48. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905-917.
49. Lam DD, Przydzial MJ, Ridley SH, et al. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology. 2008;149(3):1323-1328.
50. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebocontrolled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245-256.
51. Arena Pharmaceuticals. FDA Briefing Document; NDA 22529 Lorqess (lorcaserin hydrocloride) Tablets, 10 mg. 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMateria ls/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM225631.pdf. Accessed February 4, 2011.
52. FDA Issues Complete Response Letter for Lorcaserin New Drug Application. Press release from Arena Pharmaceuticals, Inc.; 2010 Oct 22. http://www.eisai.com/presskits/LorcaserinPDUFA.FINAL.pdf. Accessed February 4, 2011.
53. Rapport MM, Green AA, Page IH. Serum vasoconstrictor, serotonin; isolation and characterization. J Biol Chem. 1948;176(3):1243-1251.
54. Rapport MM, Green AA, Page IH. Crystalline Serotonin. Science. 1948;108(2804):329-330.
55. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355-366.
56. Lechin F, van der Dijs B, Hernandez-Adrian G. Dorsal raphe vs median raphe serotonergic antagonism. Anatomical, physiological, behavioral, neuroendocrinological, neuropharmacological and clinical evidences: relevance for neuropharmacological therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(4):565-585.
57. Medeiros MA, Costa-e-Sousa RH, Olivares EL, Cortes WS, Reis LC. A reassessment of the role of serotonergic system in the control of feeding behavior. An Acad Bras Cienc. 2005;77(1):103-111.
58. De Fanti BA, Hamilton JS, Horwitz BA. Meal-induced changes in extracellular 5-HT in medial hypothalamus of lean (Fa/Fa) and obese (fa/fa) Zucker rats. Brain Res. 2001;902(2):164-170.
59. Ohliger-Frerking P, Horwitz BA, Horowitz JM. Serotonergic dorsal raphe neurons from obese zucker rats are hyperexcitable. Neuroscience. 2003;120(3):627-634.
60. Fetissov SO, Meguid MM. Serotonin delivery into the ventromedial nucleus of the hypothalamus affects differently feeding pattern and body weight in obese and lean Zucker rats. Appetite. 2010;54(2): 346-353.
61. Park S, Harrold JA, Widdowson PS, Williams G. Increased binding at 5-HT(1A), 5-HT(1B), and 5-HT(2A) receptors and 5-HT transporters in diet-induced obese rats. Brain Res. 1999;847(1):90-97.
62. Costa E, Groppetti A, Revuelta A. Action of fenfluramine on monoamine stores of rat tissues. Br J Pharmacol. 1971;41(1):57-64.
63. Blundell JE, Leshem MB. Central action of anorexic agents: effects of amphetamine and fenfluramine in rats with lateral hypothalamic lesions. Eur J Pharmacol. 1974;28(1):81-88.
64. Gotestam KG, Andersson BE. Self-administration of amphetamine analogues in rats. Pharmacol Biochem Behav. 1975;3(2): 229-233.
65. Ghosh MN, Parvathy S. Tolerance pattern of the anorexigenic action of amphetamines, fenfluramine, phenmetrazine and diethylpropion in rats. Br J Pharmacol. 1976;57(4):479-485.
66. Garattini S, Mennini T, Samanin R. From fenfluramine racemate to d-fenfluramine. Specificity and potency of the effects on the serotoninergic system and food intake. Ann N Y Acad Sci. 1987;499:156-166.
67. Vivero LE, Anderson PO, Clark RF. A close look at fenfluramine and dexfenfluramine. J Emerg Med. 1998;16(2):197-205.
68. Rothman RB, Baumann MH. Serotonin releasing agents. Neurochemical, therapeutic and adverse effects. Pharmacol Biochem Behav. 2002; 71(4):825-836.
69. Mennini T, Fracasso C, Cagnotto A, et al. In vitro and in vivo effects of the anorectic agent dexfenfluramine on the central serotoninergic neuronal systems of non-human primates. A comparison with the rat. Naunyn Schmiedebergs Arch Pharmacol. 1996;353(6): 641-647.
70. Blundell JE, Tombros E, Rogers PJ, Latham CJ. Behavioural analysis of feeding: implications for the pharmacological manipulation of food intake in animals and man. Prog Neuropsychopharmacol. 1980;4(4-5): 319-326.
71. Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE. Serotonergic drugs:effects on appetite expression and use for the treatment of obesity. Drugs. 2007;67(1):27-55.
72. Boschmann M, Frenz U, Murphy CM, Noack R. Changes in energy metabolism and metabolite patterns of obese rats after application of dexfenfluramine. Pharmacol Biochem Behav. 1996;53(3): 549-558.
73. Bray GA. A concise review on the therapeutics of obesity. Nutrition. 2000;16(10):953-960.
74. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9): 581-588.
75. Teramae CY, Connolly HM, Grogan M, Miller FA Jr. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc. 2000;75(5):456-461.
76. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335(9): 609-616.
77. Weintraub M, Sundaresan PR, Madan M, et al. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther. 1992;51(5):586-594.
78. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase. Clin Pharmacol Ther. 1992;51(5):608-614.
79. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther. 1992;51(5):595-601.
80. Weintraub M, Sundaresan PR, Schuster B, Moscucci M, Stein EC. Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine. Clin Pharmacol Ther. 1992;51(5):602-607.
81. FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen); 1997:P97-32.
82. Gundlah C, Martin KF, Heal DJ, Auerbach SB. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther. 1997;283(2):581-591.
83. Tao R, Fray A, Aspley S, Brammer R, Heal D, Auerbach S. Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine. Eur J Pharmacol. 2002;445(1-2): 69-81.
84. McGuirk J, Muscat R, Willner P. Effects of chronically administered fluoxetine and fenfluramine on food intake, body weight and the behavioural satiety sequence. Psychopharmacology (Berl). 1992;106(3): 401-407.
85. Halford JC, Wanninayake SC, Blundell JE. Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav. 1998;61(2):159-168.
86. Burton MJ, Cooper SJ, Popplewell DA. The effect of fenfluramine on the microstructure of feeding and drinking in the rat. Br J Pharmacol. 1981;72(4):621-633.
87. Willner P, McGuirk J, Phillips G, Muscat R. Behavioural analysis of the anorectic effects of fluoxetine and fenfluramine. Psychopharmacology (Berl). 1990;102(2):273-277.
88. Blundell JE, Rogers PJ, Hill AJ. Behavioural structure and mechanisms of anorexia: calibration of natural and abnormal inhibition of eating. Brain Res Bull. 1985;15(4):371-376.
89. Tallett AJ, Blundell JE, Rodgers RJ. Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats. Behav Brain Res. 2009;198(2):359-365.
90. Rogers PJ, Blundell JE. Effect of anorexic drugs on food intake and the micro-structure of eating in human subjects. Psychopharmacology (Berl). 1979;66(2):159-165.
91. Hill AJ, Blundell JE. Sensitivity of the appetite control system in obese subjects to nutritional and serotoninergic challenges. Int J Obes. 1990;14(3):219-233.
92. Lawton CL, Wales JK, Hill AJ, Blundell JE. Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obes Res. 1995;3(4):345-356.
93. Breisch ST, Zemlan FP, Hoebel BG. Hyperphagia and obesity following serotonin depletion by intraventricular p-chlorophenylalanine. Science. 1976;192(4237):382-385.
94. Saller CF, Stricker EM. Hyperphagia and increased growth in rats after intraventricular injection of 5,7-dihydroxytryptamine. Science. 1976;192(4237):385-387.
95. Auerbach SB, Lundberg JF, Hjorth S. Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systemic administration. Neuropharmacology. 1995;34(1):89-96.
96. Gundlah C, Hjorth S, Auerbach SB. Autoreceptor antagonists enhance the effect of the reuptake inhibitor citalopram on extracellular 5-HT: this effect persists after repeated citalopram treatment. Neuropharmacology. 1997;36(4-5):475-482.
97. Popa D, Cerdan J, Reperant C, et al. A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain. Eur J Pharmacol. 2010:25;628(1-3):83-90.
98. Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol. 1997;121(8): 1613-1618.
99. Jackson HC, Needham AM, Hutchins LJ, Mazurkiewicz SE, Heal DJ. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol. 1997;121(8):1758-1762.
100. Faria AN, Ribeiro Filho FF, Kohlmann NE, Gouvea Ferreira SR, Zanella MT. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. Diabetes Obes Metab. 2005;7(3):246-253.
101. Astrup A. Macronutrient balances and obesity: the role of diet and physical activity. Public Health Nutr. 1999;2(3A):341-347.
102. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord. 1999;23(10):1016-1024.
103. Walsh KM, Leen E, Lean ME. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes Relat Metab Disord. 1999;23(10):1009-1015.
104. Connoley IP, Liu YL, Frost I, Reckless IP, Heal DJ, Stock MJ. Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol. 1999;126(6):1487-1495.
105. Heusser K, Engeli S, Tank J, et al. Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. J Clin Endocrinol Metab. 2007;92(4):1560-1563.
106. Heusser K, Tank J, Diedrich A, et al. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther. 2006;79(5):500-508.
107. Lechin F, van der Dijs B. Acute effects of sibutramine administration on the autonomic nervous system in obese subjects. Clin Pharmacol Ther. 2007;81(3):326; author reply 326-327.
108. Birkenfeld AL, Schroeder C, Boschmann M, et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation. 2002;106(19):2459-2465.
109. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002;71(4):533-554.
110. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev. 1994;46(2):157-203.
111. Garfield AS, Heisler LK. Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009;587(Pt 1): 49-60.
112. Banas SM, Doly S, Boutourlinsky K, et al. Deconstructing antiobesity compound action: requirement of serotonin 5-HT2B receptors for dexfenfluramine anorectic effects. Neuropsychopharmacology. 2011; 36(2):423-433.
113. Launay JM, Herve P, Peoc'h K, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med. 2002;8(10):1129-1135.
114. Nebigil CG, Hickel P, Messaddeq N, et al. Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and function. Circulation. 2001;103(24):2973-2979.
115. Mochizuki D, Yuyama Y, Tsujita R, Komaki H, Sagai H. Cloning and expression of the human 5-HT1B-type receptor gene. Biochem Biophys Res Commun. 1992;185(2):517-523.
116. Nothen MM, Erdmann J, Shimron-Abarbanell D, Propping P. Identif ication of genetic variation in the human serotonin 1D beta receptor gene. Biochem Biophys Res Commun. 1994;205(2): 1194-1200.
117. Bruinvels AT, Landwehrmeyer B, Gustafson EL, et al. Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology. 1994; 33(3-4):367-386.
118. Grignaschi G, Sironi F, Samanin R. The 5-HT1B receptor mediates the effect of d-fenfluramine on eating caused by intra-hypothalamic injection of neuropeptide Y. Eur J Pharmacol. 1995;274(1-3): 221-224.
119. Neill JC, Cooper SJ. Selective reduction by serotonergic agents of hypertonic saline consumption in rats: evidence for possible 5-HT1C receptor mediation. Psychopharmacology (Berl). 1989;99(2): 196-201.
120. Simansky KJ. Serotonergic control of the organization of feeding and satiety. Behav Brain Res. 1996;73(1-2):37-42.
121. Lee MD, Simansky KJ. CP-94, 253: a selective serotonin1B (5-HT1B) agonist that promotes satiety. Psychopharmacology (Berl). 1997; 131(3):264-270.
122. Lucas JJ, Yamamoto A, Scearce-Levie K, Saudou F, Hen R. Absence of fenfluramine-induced anorexia and reduced c-Fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice. J Neurosci. 1998;18(14):5537-5544.
123. Bouwknecht JA, van der Gugten J, Hijzen TH, Maes RA, Hen R, Olivier B. Male and female 5-HT(1B) receptor knockout mice have higher body weights than wildtypes. Physiol Behav. 2001;74(4-5): 507-516.
124. Elmquist JK, Ahima RS, Maratos-Flier E, Flier JS, Saper CB. Leptin activates neurons in ventrobasal hypothalamus and brainstem. Endocrinology. 1997;138(2):839-842.
125. Elmquist JK, Elias CF, Saper CB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron. 1999;22(2): 221-232.
126. Schwartz MW, Baskin DG, Kaiyala KJ, Woods SC. Model for the regulation of energy balance and adiposity by the central nervous system. Am J Clin Nutr. 1999;69(4):584-596.
127. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005;8(5):571-578.
128. Heisler LK, Jobst EE, Sutton GM, et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron. 2006;51(2):239-249.
129. Martin JR, Bos M, Jenck F, et al. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther. 1998;286(2):913-924.
130. Kennett GA, Curzon G. Potencies of antagonists indicate that 5-HT1C receptors mediate 1-3(chlorophenyl)piperazine-induced hypophagia. Br J Pharmacol. 1991;103(4):2016-2020.
131. Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature. 1995;374(6522): 542-546.
132. Vickers SP, Clifton PG, Dourish CT, Tecott LH. Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice. Psychopharmacology (Berl). 1999;143(3):309-314.
133. Nonogaki K, Strack AM, Dallman MF, Tecott LH. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med. 1998;4(10):1152-1156.
134. Fletcher PJ, Tampakeras M, Sinyard J, Slassi A, Isaac M, Higgins GA. Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice. Neuropharmacology. 2009;57(3):259-267.
135. Heisler LK, Cowley MA, Tecott LH, et al. Activation of central melanocortin pathways by fenfluramine. Science. 2002;297(5581): 609-611.
136. Dalton GL, Lee MD, Kennett GA, Dourish CT, Clifton PG. Serotonin 1B and 2C receptor interactions in the modulation of feeding behaviour in the mouse. Psychopharmacology (Berl). 2006;185(1):45-57.
137. Zhou L, Sutton GM, Rochford JJ, et al. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab. 2007;6(5):398-405.
138. Hayashi A, Suzuki M, Sasamata M, Miyata K. Thermogenic effect of YM348, a novel 5-HT2C-receptor agonist, in rats. J Pharm Pharmacol. 2004;56(12):1551-1556.
139. Hayashi A, Suzuki M, Sasamata M, Miyata K. Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats. Psychopharmacology (Berl). 2005;178(2-3):241-249.
140. Lorcaserin Phase 3 clinical trial in patients with type 2 diabetes shows statistically significant weight loss. Press Release Arena Pharmaceuticals. November 9, 2010.
141. Mancini MC, Halpern A. Pharmacological treatment of obesity. Arq Bras Endocrinol Metabol. 2006;50(2):377-389.
142. Zhou Z, Zhen J, Karpowich NK, Law CJ, Reith ME, Wang DN. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat Struct Mol Biol. 2009;16(6): 652-657.
143. Luscombe GP, Hopcroft RH, Thomas PC, Buckett WR. The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology. 1989;28(2):129-134.
144. Luscombe GP, Slater NA, Lyons MB, Wynne RD, Scheinbaum ML, Buckett WR. Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl. Psychopharmacology (Berl). 1990;100(3): 345-349.
145. Bae SK, Cao S, Seo KA, et al. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes. Drug Metab Dispos. 2008; 36(8):1679-1688.
146. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369(9555):71-77.
147. Talbot PS, Bradley S, Clarke CP, et al. Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11) C-DASB in healthy humans. Neuropsychopharmacology. 2010;35(3):741-751.
148. Smith BM, Smith JM, Tsai JH, et al. Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J Med Chem. 2008;51(2): 305-313.
149. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008; 325(2):577-587.
150. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring). 2009;17(3):494-503.
151. Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther. 1991;50(3):330-337.
152. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res. 1999;7(2):189-198.
153. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res. 1996;4(3):263-270.
154. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. A comparison of sibutramine and dexfenfluramine in the treatment of obesity. Obes Res. 1998;6(4):285-291.
155. Guven A, Koksal N, Cetinkaya A, Sokmen G, Ozdemir R. Effects of the sibutramine therapy on pulmonary artery pressure in obese patients. Diabetes Obes Metab. 2004;6(1):50-55.
156. Bach DS, Rissanen AM, Mendel CM, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res. 1999;7(4):363-369.
157. FDA Recommends Against the Continued Use of Meridia (sibutramine). Questions and Answers. FDA press release. October 8, 2010.
158. Bond DS, Phelan S, Wolfe LG, et al. Becoming physically active after bariatric surgery is associated with improved weight loss and healthrelated quality of life. Obesity (Silver Spring). 2009;17(1):78-83.
159. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005;82(1 Suppl):222S-225S.
160. Fine JT, Colditz GA, Coakley EH, et al. A prospective study of weight change and health-related quality of life in women. JAMA. 1999; 282(22):2136-2142.
161. Digenio AG, Mancuso JP, Gerber RA, Dvorak RV. Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial. Ann Intern Med. 2009;150(4):255-262.
162. Kaukua JK, Pekkarinen TA, Rissanen AM. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. Int J Obes Relat Metab Disord. 2004; 28(4):600-605.
163. Wilfley DE, Crow SJ, Hudson JI, et al. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry. 2008;165(1): 51-58.
164. Pillitteri JL, Shiffman S, Rohay JM, Harkins AM, Burton SL, Wadden TA. Use of dietary supplements for weight loss in the United States: results of a national survey. Obesity (Silver Spring). 2008;16(4): 790-796.
165. Lenz TL, Hamilton WR. Supplemental products used for weight loss. J Am Pharm Assoc (2003). 2004;44(1):59-67; quiz 67-58.
166. Dwyer JT, Allison DB, Coates PM. Dietary supplements in weight reduction. J Am Diet Assoc. 2005;105(5 Suppl 1):S80-S86.
167. Bui LT, Nguyen DT, Ambrose PJ. Blood pressure and heart rate effects following a single dose of bitter orange. Ann Pharmacother. 2006; 40(1):53-57.
168. Carlson JC, Riley JC. A consideration of some notable aging theories. Exp Gerontol. 1998;33(1-2):127-134.
169. Merry BJ. Dietary restriction in rodents-delayed or retarded ageing? Mech Ageing Dev. 2005;126(9):951-959.
170. Smith DL Jr, Robertson HT, Desmond RA, Nagy TR, Allison DB. No compelling evidence that sibutramine prolongs life in rodents despite providing a dose-dependent reduction in body weight. Int J Obes (Lond). Nov 16, 2010. [Epub ahead of print].